A Phase 1 interventional study of OPT101 in Diabetes Mellitus, Type 1, sponsored by Op-T LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Op-T LLC · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 801st largest by enrollment of the 1,242 interventional ones that give a count, is one of 62 that started in 2022, is one of 147 in phase 1, and was the 1,181st registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 31–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 5–40
Wayne State University · Sites in United States
Ages 16–20
Medtronic MiniMed, Inc. · Sites in United States
Ages 2–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,458 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 206 · Phase 2 267 · Phase 3 167 · Phase 4 74
First in 1983; this study’s year is marked. 62 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 1,242 interventional studies, 64 across the 203 observational. Of the 1,117 that completed or were terminated, 563 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,458 have an industry lead sponsor. The 10 most frequent:
Op-T LLC is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Op-T LLC has 2 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
117 of the studies in Diabetes Mellitus, Type 1 with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT06334133Phase 3vTv TherapeuticsCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | 2027-04 |
| NCT07056699Phase 3The University of Texas Health Science Center at San AntonioSGLT2i, Pioglitazone, and Ketone Production in T1D | 2027-06-01 |
Add all 117 to your calendar (.ics) → With an account.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.
This study is a randomized, multicenter, placebo-controlled, double blinded study that will be conducted as a multiple ascending doses (MAD) study to measure safety, the immunological, and the clinical effects of 1.1 and 2.8 mg/kg doses of OPT101 that were found to be safe in the OPT-100-30 (IND 150941) Phase 1a study performed in healthy volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women must agree to use one of the following methods of for the duration of the clinical trial: systemic hormonal contraceptive (oral, injected, transdermal), intrauterine device, double barrier (e.g., cervical cap or diaphragm with condom or spermicide). Men with female partners must agree to use double barrier contraception, unless their partner is using systemic hormonal contraceptives or has an intrauterine device.
-
Exclusion Criteria:
Patients with abnormal laboratory test values in screening blood samples. In particular patients with the following should be excluded:
i. Patients with abnormal coagulation panel at screening such as abnormal PT or or fibrinogen ii. Abnormal liver function tests:
1. Liver enzyme abnormalities (except in the case of known Gilbert's syndrome) 2. or ALT ≥3x and total ≥2x ULN 3. AST or ALT ≥5x ULN 4. AST or ALT ≥3x ULN if associated with appearance or worsening of rash or hepatitis symptoms iii. Abnormal counts (\<150,000mcL or > 450,000mcL) iv. Abnormal white blood cell counts (\<3mL or > 11mL) v. Abnormal (\<50mg/dL or >1.10mg/dL) vi. Abnormal Factor VIII (> 160%) vii. Abnormal D-Dimer (> 500ng/mL FEU) 11. Patients planning to undergo elective procedures or surgeries at any time after signing the ICF through the follow-up visit.
12. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
13. Recent history of bleeding or bleeding disorders or any condition whereby in the opinion of the treating investigator giving anti-coagulation during treatment would be .
14. History of to antihistamines. 15. Weight is over 250lbs. 16. Patients with active drug or alcohol abuse within 1 year prior to screening 17. Patient is participating in a clinical trial of another drug or device, including patients who have participated in another study for a duration of 5 half-lives of the investigational agent.
18. Patient is a prisoner 19. Investigators could exclude patients with any medical condition, including, but not limited to, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal, or a psychiatric condition that, in the opinion of the Investigator, could compromise the participant's ability to participate in this study.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
9 subjects (6 investigational product:3 placebo)
Drug: OPT101
9 subjects (6 investigational product:3 placebo)
Drug: OPT101
15-mer peptide derived from the sequence of mouse CD154.
Number of Treatment-related AE's as Assessed by CTCAE v4.0
Number of treatment-related adverse events as assessed by CTCAE v4.0 over 42 days for all participants.
Time frame: 42 days
Serum Samples Collected to Determine AUC0-t
Blood samples will be collected to determine the serum concentrations of OPT101 (mg/kg)
Time frame: 42 days
Serum Samples Collected to Determine Cmax
Blood samples will be collected to determine the serum Cmax levels of OPT101 (pg/mL)
Time frame: 42 Days
Serum Samples Collected to Determine CL/F
Blood samples will be collected to determine the CL/F values of OPT101 (mL/min/kg)
Time frame: 42 days
Serum Samples Collected to Determine t1/2
Blood samples will be collected to determine the serum concentrations of OPT101 (mg/kg)
Time frame: 42 days
Serum Samples Collected to Determine HbA1C From Baseline Pre Mixed Meal Tolerance Test to Day 56 Pre Mixed Meal Tolerance
Serum samples collected to determine HbA1C levels from baseline pre mixed meal tolerance to Day 56 pre mixed meal tolerance test of OPT101 (mmol/mole)
Time frame: 56 days
Serum Samples Collected to Determine C-peptide Post Mixed Meal Tolerance Test
Serum samples collected to determine C-Peptide values (ng/mL), post mixed-meal tolerance for End of Study (EOS).
Time frame: 42 days
Serum Samples Collected to Determine Glucose Levels Post Mixed Meal Tolerance Test at End-of-Study
Serum samples collected to determine glucose levels (mmol/L) post mixed meal tolerance test at End-of-Study
Time frame: 42 days
Able and willing and able to give informed consent for the trial Male or female aged ≥18 years on the day of signing informed consent Diagnosis of T1D within the last 20 years Is medically stable based on physical examination, medical history, laboratory results, and vital signs performed at screening Women of childbearing potential must have a negative highly sensitive serum test (beta- human chorionic gonadotropin) at screening and a negative urine pregnancy test at the Visit 1
| Milestone | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM |
|---|---|---|---|
| Started | 8 | 8 | 8 |
| Completed | 6 | 6 | 6 |
| Not completed | 2 | 2 | 2 |
Blood samples will be collected to determine the serum concentrations of OPT101 (mg/kg)
| pg/mL*min | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM |
|---|---|---|---|
| Serum Samples Collected to Determine AUC0-t | 2197643 ± 1436405 | 1839862 ± 2443513 | NA ± NA |
Blood samples will be collected to determine the serum Cmax levels of OPT101 (pg/mL)
| pg/mL | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM |
|---|---|---|---|
| Serum Samples Collected to Determine Cmax | 71333 ± 47759 | 56764 ± 77354 | NA ± NA |
Number of treatment-related adverse events as assessed by CTCAE v4.0 over 42 days for all participants.
| Adverse Events | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM |
|---|---|---|---|
| Number of Treatment-related AE's as Assessed by CTCAE v4.0 | 1 | 1 | 0 |
Blood samples will be collected to determine the CL/F values of OPT101 (mL/min/kg)
| mL/min/kg | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM |
|---|---|---|---|
| Serum Samples Collected to Determine CL/F | 0.40 ± 0.14 | 3.84 ± 3.15 | NA ± NA |
Blood samples will be collected to determine the serum concentrations of OPT101 (mg/kg)
| minutes | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM |
|---|---|---|---|
| Serum Samples Collected to Determine t1/2 | 2.3 ± 0.9 | 2.0 ± 0.4 | NA ± NA |
Serum samples collected to determine HbA1C levels from baseline pre mixed meal tolerance to Day 56 pre mixed meal tolerance test of OPT101 (mmol/mole)
| mmol/mole | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM |
|---|---|---|---|
| Serum Samples Collected to Determine HbA1C From Baseline Pre Mixed Meal Tolerance Test to Day 56 Pre Mixed Meal Tolerance | 0.53 ± 0.83 | 0.12 ± 0.48 | 0.06 ± 0.43 |
Serum samples collected to determine C-Peptide values (ng/mL), post mixed-meal tolerance for End of Study (EOS).
| ng/mL | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM |
|---|---|---|---|
| Serum Samples Collected to Determine C-peptide Post Mixed Meal Tolerance Test | 0.03 ± 0.07 | 0.07 ± 0.26 | 0.16 ± 0.26 |
Serum samples collected to determine glucose levels (mmol/L) post mixed meal tolerance test at End-of-Study
| mmol/L | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM |
|---|---|---|---|
| Serum Samples Collected to Determine Glucose Levels Post Mixed Meal Tolerance Test at End-of-Study | 0.53 ± 0.83 | 0.12 ± 0.48 | 0.06 ± 0.43 |
Collected over From enrollment until end of study, 42 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.1 mg/kg OPT101 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 2.8 mg/kg OPT101 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Placebo OPT101-PTM | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Event | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM |
|---|---|---|---|
| Infusion site extravasationSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/8 |
| Event | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM |
|---|---|---|---|
| FatigueGeneral disorders | 1/6 | 1/6 | 0/8 |
3 females received the 1.1 mg/kg dose, 3 and females received the 2.8 mg/kg dose. 3 males received the 1.1 mg/kg dose, and 3 males received the 2.8 mg/kg dose. 5 females and 3 males were administered placebo between the 2 cohorts included in the study.
| Age, Customized(Years) | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM | Total |
|---|---|---|---|---|
| Mean Years | 28.8 ± 4.3 | 32.3 ± 10.2 | 32.0 ± 7.3 | 31.1 ± 7.4 |
| Sex: Female, Male(Participants) | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM | Total |
|---|---|---|---|---|
| Female | 3 | 3 | 5 | 11 |
| Male | 3 | 3 | 3 | 9 |
| Race/Ethnicity, Customized(Participants) | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM | Total |
|---|---|---|---|---|
| % White | 6 | 6 | 6 | 18 |
| % Hispanic or Latino | 2 | 2 | 0 | 4 |
| % Black or African American | 0 | 0 | 1 | 1 |
| % Asian, Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Weight of Subject (kg)(kg) | 1.1 mg/kg OPT101 | 2.8 mg/kg OPT101 | Placebo OPT101-PTM | Total |
|---|---|---|---|---|
| Mean | 74.0 (65.5 to 87.3) | 75.2 (49.0 to 93.1) | 79.3 (60.8 to 101.8) | 76.5 (49.0 to 101.8) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Feb 2024, 16 months.
Results were first posted in Aug 2026, 2 years 5 months after primary completion.
Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 16 months is above that.
Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: OPT101
Op-T LLC